论文部分内容阅读
我科应用假单胞注射液（ＰＶＩ）治疗恶性胸腔积液２１例，全部病例经组织学和／或细胞学检查证实，其中肺癌胸腔积液１９例，胸腹腔转移性腺癌１例，梅格氏综合征１例，在２１例中ＣＲ９例（４２．８％），ＰＲ７的（３３．３％），总有效率７６．１％，该药的主要不良反应是发热，其发生率９０．４％，其次是胸痛，这些反应经处理大部分可以耐受。
In our department, 21 cases of malignant pleural effusions were treated with PVI, and all cases were confirmed by histological and/or cytological examinations. Among them, 19 cases were lung pleural effusion, 1 case was metastatic adenocarcinoma of thoracic cavity, and Meg 1 case of Syndrome, in 9 cases CR9 cases (42.8%), PR7 (33.3%), the total effective rate of 76.1%, the drug’s main adverse reaction is fever, the incidence of 90. 4%, followed by chest pain, these reactions can be tolerated most of the time.